Eileen Schedel
Adult Health · Aurora, ILNPI 1548257330
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,538 of the $20,671 with a category attached, or 75.2%. AbbVie accounts for 86.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $10,566 and has fallen 90.7% since, to $980 in 2025. Among adult health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $64.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$257
- Biogen$221
- Jazz Pharmaceuticals Inc.$167
- CSL Behring$148
- plus $896 from 16 others
What the payments were for
- Speaking & faculty fees$15,53875%
- Food & beverage$4,74523%
- Education$3882%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 164 | $17,933 |
| Teva Pharmaceuticals USA, Inc. | 87 | $1,049 |
| Lundbeck LLC | 12 | $257 |
| Biogen | 10 | $221 |
| Jazz Pharmaceuticals Inc. | 2 | $167 |
| CSL Behring | 6 | $148 |
| Livanova USA, Inc. | 7 | $134 |
| Genentech USA, Inc. | 5 | $125 |
| Corium, LLC | 6 | $119 |
| TG Therapeutics, Inc. | 4 | $85 |
| Cala Health, Inc. | 2 | $82 |
| Bristol Myers Squibb | 3 | $61 |
| Amgen | 3 | $59 |
| Octapharma USA, Inc. | 1 | $37 |
| Pfizer | 2 | $32 |
| Novartis | 1 | $30 |
| Lilly USA, LLC | 1 | $26 |
| Impel Pharmaceuticals Inc. | 1 | $25 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $20 |
| Abbott | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,671 in reported general payments places this provider in the 95th percentile of 553 adult health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 11 | $131,337 |
| UbrelvyUbrogepant | 47 | $94,871 |
| Nurtec OdtRimegepant Sulfate | 36 | $81,105 |
| Aimovig AutoinjectorErenumab-Aooe | 39 | $66,557 |
| Teriflunomide | 38 | $61,129 |
| Emgality PenGalcanezumab-Gnlm | 52 | $56,923 |
| QuliptaAtogepant | 13 | $24,854 |
| NeuproRotigotine | 11 | $23,900 |
| Emgality SyringeGalcanezumab-Gnlm | 16 | $16,189 |
| Dalfampridine ErDalfampridine | 40 | $15,578 |
| Gabapentin | 411 | $9,450 |
| Galantamine ErGalantamine Hbr | 99 | $9,003 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 170 | $8,121 |
| Rasagiline Mesylate | 37 | $6,093 |
| Memantine Hcl | 270 | $5,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $17,933 | $119,72560 claims |
| PfizerNurtec Odt | $32 | $81,10536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 553 adult health providers in Illinois.
Other adult health in Aurora
- Carmen JanichAurora$5K
- Kimberly KearnsHoffman Estates$531K
- Leslie ForresterArlington Heights$97K
- Colleen FolkersChicago$86K
- Matthew BurkeChicago$44K
- Jacklyn GideonChicago$38K
- Jennifer GreenfieldChicago$35K
- Tammy PomaChicago$32K
- Tammy BrownNorth Chicago$31K
- Julia BuesserGurnee$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.